PLM responses are significantly reduced in patients with SSc, confirming the role of NO-mediated endothelial dysfunction in SSc, independent of disease subtype or treatment status. PLM may serve as a noninvasive biomarker for microvascular health in SSc and underscore the need for therapies that directly target the endothelium. Larger, longitudinal studies are warranted to confirm these results and explore PLM's prognostic utility.
Guella et al. (Mon,) studied this question.